Description
Pharmacological action
Antiviral. Specifically inhibits influenza A and B viruses, the coronavirus associated with severe acute respiratory syndrome. According to the mechanism of antiviral action, it belongs to fusion (fusion) inhibitors, interacts with the hemagglutinin of the virus and prevents the fusion of the lipid membrane of the virus and cell membranes. It has a moderate immunomodulatory effect. It has interferon-inducing activity, stimulates humoral and cellular immunity reactions, macrophage phagocytic function, increases the body’s resistance to viral infections. It reduces the incidence of complications associated with a viral infection, as well as exacerbations of chronic bacterial diseases.
Therapeutic efficacy in viral infections is manifested in a decrease in the severity of general intoxication and clinical events, a reduction in the duration of the disease, and a decrease in the risk of complications.
Refers to low toxicity compounds (LD50> 4 g / kg). It does not have any negative effects on the human body when administered orally in recommended doses.
Indications
Prevention and treatment in adults and children: influenza A and B, acute respiratory viral infections, severe acute respiratory syndrome (including complicated by bronchitis, pneumonia) secondary immunodeficiency complex treatment of chronic bronchitis, pneumonia and recurrent herpes infection.
Prevention of postoperative infectious complications and normalization of immune status.
Complex therapy of acute intestinal infections of rotavirus etiology in children older than 3 years.
Contraindications
Children under 3 years of age hypersensitivity to umifenovir.
Recommended Use Inside, before eating.
Single dose (depending on age):
Age
Single dose of
from 3 to 6 years old
50 mg (1 tablet to 50 mg)
from 6 to 12 years old
100 mg (2 tablets to 50 mg or 1 tablet 100 mg)
over 12 years old and adults
200 mg (4 tablets of 50 mg or 2 tablets of 100 mg)
Indication of
Scheme of taking the drug
In children from 3 years of age and adults:
Non-specific prophylaxis in the period of an influenza epidemic and others ARVI
in a single dose 2 times a week for 3 weeks.
Non-specific prophylaxis in direct contact with patients with influenza and other acute respiratory viral infections
in a single dose 1 time per day for 10-14 days.
Treatment of influenza and other acute respiratory viral infections
per day (every 6 hours) for 5 days.
Complex therapy of chronic bronchitis, pneumonia and recurrent herpetic infection
in a single dose 4 times in a single dose 4 times a day (every 6 hours) for 5-7 days, then a single dose 2 times a week for 4 weeks.
Prevention after surgical infectious complications of
in a single dose 2 days before surgery, then 2 and 5 days after surgery.
Special instructions
Does not show central neurotropic activity and can be used in medical practice as a preventive measure in healthy individuals of various professions, including requiring increased attention and coordination of movements (drivers of transport, operators, etc.).
Composition
Tablets, film-coated, from white to white with a creamy tint, round, biconvex, rough, fractured from white to white with a greenish yellowish or creamy tint.
1 tab. Umifenovir hydrochloride 100 mg
Excipients: lactose monohydrate – 0.1722 g, povidone K25 (medium-molecular weight polyvinyl pyrrolidone) – 0.0064 g, crospovidone – 0.0094 g, colloidal silicon dioxide (aerosil) – 0.009 g, magnesium stelerate – 3 g membranes: Opadry II white [lactose monohydrate – 36%, hypromellose – 28%, titanium dioxide – 26%, macrogol-4000 (polyethylene glycol 4000) – 10%] -0.012 g.
Side effects
Rarely: allergic reaction.
Storage conditions
At a temperature not exceeding 25 ° C. Keep out of the reach of children.
Shelf life
2 years. Do not use after the expiration date indicated on the package.
active substance
umifenovir
pharmacy terms and conditions without a prescription
The dosage form of
tablet
Appointment
for Adults, Detyam over 6 years
